Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency

Nature Communications

Volumn 7, Issue , 2016, Pages

  Richmond, Bradley W ^a,b   Brucker, Robert M ^c   Han, Wei ^a   Du, Rui Hong ^a   Zhang, Yongqin ^a   Cheng, Dong Sheng ^a   Gleaves, Linda ^a   Abdolrasulnia, Rasul ^a   Polosukhina, Dina ^b   Clark, Peter E ^b   Bordenstein, Seth R ^b   Blackwell, Timothy S ^a,b,d   Polosukhin, Vasiliy V ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOCYTE ELASTASE; MACROPHAGE ELASTASE; ROFLUMILAST; SECRETORY COMPONENT; SECRETORY IMMUNOGLOBULIN; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; MATRIX METALLOPEPTIDASE 12, MOUSE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR;

BACTERIUM; IMMUNE RESPONSE; INHIBITOR; PATHOLOGY; PHENOTYPE; RODENT;

AIRWAY REMODELING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; EMPHYSEMA; FIRMICUTES; GENE DELETION; INFLAMMATORY CELL; LEUKOCYTE; LUNG ALVEOLUS WALL; MOLECULAR IMAGING; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEOBACTERIA; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; TRANSCRIPTION INITIATION; AGING; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LUNG; MICROBIOLOGY; MICROFLORA; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RESPIRATORY MUCOSA;

BACTERIA (MICROORGANISMS); MUS;

AGING; AIRWAY REMODELING; AMINOPYRIDINES; ANIMALS; BENZAMIDES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN A, SECRETORY; LEUKOCYTE ELASTASE; LUNG; MATRIX METALLOPROTEINASE 12; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROBIOTA; NF-KAPPA B; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RECEPTORS, POLYMERIC IMMUNOGLOBULIN; RESPIRATORY MUCOSA;

EID: 84964012332     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11240     Document Type: Article

References (53)

1. Vestbo J., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 187, 347-365 (2013
2. Hogg J. C., Macklem P. T., & Thurlbeck W. M. Site and nature of airway obstruction in chronic obstructive lung disease. N. Engl. J. Med. 278, 1355-1360 (1968
3. Hogg J. C., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 2645-2653 (2004
4. McDonough J. E., et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 365, 1567-1575 (2011
5. Baraldo S., Turato G., & Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration 84, 89-97 (2012
6. Decramer M., Janssens W., & Miravitlles M. Chronic obstructive pulmonary disease. Lancet 379, 1341-1351 (2012
7. Tuder R. M., & Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 122, 2749-2755 (2012
8. Wright J. L., et al. Morphology of peripheral airways in current smokers and ex-smokers. Am. Rev. Respir. Dis. 127, 474-477 (1983
9. Rutgers S. R., et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 55, 12-18 (2000
10. Knowles M. R., & Boucher R. C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 109, 571-577 (2002
11. Parker D., & Prince A. Innate immunity in the respiratory epithelium. Am. J. Respir. Cell. Mol. Biol. 45, 189-201 (2011
12. Ganesan S., Comstock A. T., & Sajjan U. S. Barrier function of airway tract epithelium. Tissue Barriers 1, e24997 (2013
13. Pilette C., Ouadrhiri Y., Godding V., Vaerman J. P., & Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur. Respir. J. 18, 571-588 (2001
14. Mantis N. J., Rol N., & Corthesy B. Secretory IgA?s complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 4, 603-611 (2011
15. Kaetzel C. S. Cooperativity among secretory IgA, the polymeric immunoglobulin receptor, and the gut microbiota promotes host-microbial mutualism. Immunol. Lett. 162, 10-21 (2014
16. Kaetzel C. S. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol. Rev. 206, 83-99 (2005
17. Johansen F. E., & Kaetzel C. S. Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity. Mucosal Immunol. 4, 598-602 (2011
18. Pabst O. New concepts in the generation and functions of IgA. Nat. Rev. Immunol. 12, 821-832 (2012
19. Corthesy B. Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun. Rev. 12, 661-665 (2013
20. Pilette C., et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163, 185-194 (2001
21. Polosukhin V. V. Ultrastructural of the bronchial epithelium in chronic inflammation. Ultrastruct. Pathol. 25, 119-128 (2001
22. Polosukhin V. V., et al. Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 184, 317-327 (2011
23. Gohy S. T., et al. Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-beta. Am. J. Respir. Crit. Care Med. 190, 509-521 (2014
24. Du R. H., et al. Secretory IgA from submucosal glands does not compensate for its airway surface deficiency in chronic obstructive pulmonary disease. Virchows Arch. 467, 657-665 (2015
25. Shimada S., et al. Generation of polymeric immunoglobulin receptor-deficient mouse with marked reduction of secretory IgA. J. Immunol. 163, 5367-5373 (1999
26. Johansen F. E., et al. Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. J. Exp. Med. 190, 915-922 (1999
27. Shapiro S. D. The pathogenesis of emphysema: the elastase: antielastase hypothesis 30 years later. Proc. Assoc. Am. Physicians 107, 346-352 (1995
28. Shifren A., & Mecham R. P. The stumbling block in lung repair of emphysema: elastic fiber assembly. Proc. Am. Thorac. Soc. 3, 428-433 (2006
29. Wright J. L., Cosio M., & Churg A. Animal models of chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell Mol. Physiol. 295, L1-15 (2008
30. Han W., et al. Molecular imaging of folate receptor beta positive macrophages during acute lung inflammation. Am. J. Respir. Cell Mol. Biol. 53, 50-59 (2014
31. Mocchegiani E., Giacconi R., & Costarelli L. Metalloproteases/antimetalloproteases imbalance in chronic obstructive pulmonary disease: genetic factors and treatment implications. Curr. Opin. Pulm. Med. 17 (Suppl 1) S11-S19 (2011
32. Churg A., & Wright J. L. Proteases and emphysema. Curr. Opin. Pulm. Med. 11, 153-159 (2005
33. Lungarella G., Cavarra E., Lucattelli M., & Martorana P. A. The dual role of neutrophil elastase in lung destruction and repair. Int. J. Biochem. Cell Biol. 40, 1287-1296 (2008
34. Hoenderdos K., & Condliffe A. The neutrophil in chronic obstructive pulmonary disease. Am. J. Respir. Cell. Mol. Biol. 48, 531-539 (2013
35. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., & Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen-and stress-activated protein kinase-1 (MSK1). EMBO J. 22, 1313-1324 (2003
36. Darb-Esfahani S., et al. Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma. Histopathology 56, 727-739 (2010
37. Law M., Corsino P., Parker N. T., & Law B. K. Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-kappaB using in silico molecular docking. Cancer Lett. 291, 217-224 (2010
38. Barfod K. K., et al. The murine lung microbiome in relation to the intestinal and vaginal bacterial communities. BMC Microbiol. 13, 303 (2013
39. Knights D., Costello E. K., & Knight R. Supervised classification of human microbiota. FEMS Microbiol. Rev. 35, 343-359 (2011
40. Finney L. J., Ritchie A., Pollard E., Johnston S. L., & Mallia P. Lower airway colonization and inflammatory response in COPD: a focus on Haemophilus influenzae. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 1119-1132 (2014
41. Van Eldere J., Slack M. P., Ladhani S., & Cripps A. W. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis. 14, 1281-1292 (2014
42. Martorana P. A., Beume R., Lucattelli M., Wollin L., & Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am. J. Respir. Crit. Care Med. 172, 848-853 (2005
43. Martorana P. A., et al. Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm. Med. 8, 17 (2008
44. Michalski J. M., Golden G., Ikari J., & Rennard S. I. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin. Pharmacol. Ther. 91, 134-142 (2012
45. Tashkin D. P. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin. Pharmacother. 15, 85-96 (2014
46. Rinaldi M., et al. Long-term nose-only cigarette smoke exposure induces emphysema and mild skeletal muscle dysfunction in mice. Dis. Model Mech. 5, 333-341 (2012
47. Schneeman T. A., et al. Regulation of the polymeric Ig receptor by signaling through TLRs 3 and 4: linking innate and adaptive immune responses. J. Immunol. 175, 376-384 (2005
48. Pinner N. A., Hamilton L. A., & Hughes A. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin. Ther. 34, 56-66 (2012
49. Ganesan S., et al. Combined exposure to cigarette smoke and nontypeable Haemophilus influenzae drives development of a COPD phenotype in mice. Respir. Res. 15, 11 (2014
50. Rosen F. S., et al. Primary immunodeficiency diseases. Report of a WHO Scientific Group. Clin. Exp. Immunol. 99 (Suppl 1) 1-24 (1995
51. Brandtzaeg P., et al. The clinical condition of IgA-deficient patients is related to the proportion of IgD-and IgM-producing cells in their nasal mucosa. Clin. Exp. Immunol. 67, 626-636 (1987
52. Klemola T. Immunohistochemical findings in the intestine of IgA-deficient persons: number of intraepithelial T lymphocytes is increased. J. Pediatr. Gastroenterol. Nutr. 7, 537-543 (1988
53. Caporaso J. G., et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335-336 (2010